Cambridge startup biotechnology company Walden Biosciences announced its launch today with a $51 million Series A financing led by UCB Ventures and ARCH Venture Partners. Walden is seeking to develop breakthrough therapies to treat rare and common forms of kidney disease affecting more than 1 in 7 American adults.

Links to related news articles here:

https://www.fiercebiotech.com/biotech/walden-biosciences-receives-51m-to-launch-startup-focused-kidney-disease

https://www.biospace.com/article/releases/walden-biosciences-launches-to-transform-the-treatment-of-kidney-disease/